Most chronic inflammatory illnesses include fibrosis as a pathogenic characteristic.
Extracellular matrix (ECM) components build up in excess to cause fibrosis or scarring. The …

Many local and systemic diseases especially diseases that are leading causes of death
globally like chronic obstructive pulmonary disease, atherosclerosis with ischemic heart …

Idiopathic pulmonary fibrosis (IPF) seriously threatens human life and health, and no
curative therapy is available at present. Nintedanib is the first agent approved by the US …

Lung fibrosis is a progressive fatal disease in which deregulated wound healing of lung
epithelial cells drives progressive fibrotic changes. Persistent lung injury due to oxidative …

N-acetylcysteine (NAC) is widely used because of its mucolytic effects, taking part in the
therapeutic protocols of cystic fibrosis. NAC is also administered as an antidote in …

Disruption of the extracellular matrix (ECM) and an accumulation of fibrotic lesions within
tissues are two of the distinctive hallmarks of the aging process. Tissue fibroblasts are …

Idiopathic pulmonary fibrosis (IPF) is a fatal and irreversible disease with few effective
treatments. Alveolar macrophages (AMs) are involved in the development of IPF from the …

Abstract Galectin-3 (Gal-3), a multifunctional carbohydrate-binding lectin, has emerged as a
key player in various biological processes including inflammation, cancer, cardiovascular …

Background In recent years, the pleiotropic roles of antioxidants have drawn extensive
attention in various diseases. Vitamin C is a well-known antioxidant, and it has been used to …

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease characterized
by excessive accumulation of extracellular matrix, leading to irreversible fibrosis. Emerging …